GetTopicDetailResponse(id=1f351625ead, topicName=Shionogi, introduction=Shionogi, content=null, image=null, comments=5, allHits=1197, url=https://h5.medsci.cn/topic?id=16257, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=78581, tagList=[TagDto(tagId=78581, tagName=Shionogi)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1689177, encodeId=996116891e70f, content=<a href='/topic/show?id=1f351625ead' target=_blank style='color:#2F92EE;'>#Shionogi#</a>, objectTitle=歐盟批準Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重點革蘭氏陰性病原體, objectType=article, longId=193318, objectId=de90193318ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de90193318ff, replyNumber=0, likeNumber=105, createdTime=2020-10-09, rootId=0, userName=ms5106640509429053, userId=156c28741842, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de90193318ff, moduleTitle=歐盟批準Shionogi的新型抗生素Fetcroja——用于WHO指定的所有重點革蘭氏陰性病原體, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=de90193318ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1689176, encodeId=7c4b16891e68d, content=<a href='/topic/show?id=1f351625ead' target=_blank style='color:#2F92EE;'>#Shionogi#</a>, objectTitle=Shionogi宣布在英國推出血小板生成素受體激動劑Mulpleo（lusutrombopag），用于接受侵入性治療的慢性肝病成年患者的嚴重血小板減少癥, objectType=article, longId=189673, objectId=433d1896e3eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433d1896e3eb, replyNumber=0, likeNumber=83, createdTime=2020-05-07, rootId=0, userName=ms5106640509429053, userId=156c28741842, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433d1896e3eb, moduleTitle=Shionogi宣布在英國推出血小板生成素受體激動劑Mulpleo（lusutrombopag），用于接受侵入性治療的慢性肝病成年患者的嚴重血小板減少癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=433d1896e3eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1689174, encodeId=453916891e4e7, content=<a href='/topic/show?id=1f351625ead' target=_blank style='color:#2F92EE;'>#Shionogi#</a>, objectTitle=由于英國脫歐，日本鹽野義制藥公司Shionogi計劃將總部從英國遷移到荷蘭, objectType=article, longId=162221, objectId=278416222109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=278416222109, replyNumber=0, likeNumber=84, createdTime=2019-10-04, rootId=0, userName=ms5106640509429053, userId=156c28741842, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=278416222109, moduleTitle=由于英國脫歐，日本鹽野義制藥公司Shionogi計劃將總部從英國遷移到荷蘭, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=278416222109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1689175, encodeId=266816891e57c, content=<a href='/topic/show?id=1f351625ead' target=_blank style='color:#2F92EE;'>#Shionogi#</a>, objectTitle=AMR中心和日本Shionogi合作開發(fā)COT-143單抗，治療銅綠假單胞菌感染, objectType=article, longId=176038, objectId=b5c41e6038a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5c41e6038a4, replyNumber=0, likeNumber=96, createdTime=2019-08-19, rootId=0, userName=ms5106640509429053, userId=156c28741842, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5c41e6038a4, moduleTitle=AMR中心和日本Shionogi合作開發(fā)COT-143單抗，治療銅綠假單胞菌感染, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b5c41e6038a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1689173, encodeId=e8e516891e367, content=<a href='/topic/show?id=1f351625ead' target=_blank style='color:#2F92EE;'>#Shionogi#</a>, objectTitle=FDA批準Shionogi的Mulpleta治療慢性肝病引起的血小板減少癥, objectType=article, longId=145680, objectId=994d145680d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=994d145680d1, replyNumber=0, likeNumber=90, createdTime=2018-10-21, rootId=0, userName=ms5106640509429053, userId=156c28741842, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=994d145680d1, moduleTitle=FDA批準Shionogi的Mulpleta治療慢性肝病引起的血小板減少癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=994d145680d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
